Company news

Immatics N.V. news in 2022

Immatics N.V.'s news releases, calls and decks from 2022, newest first.

View company

Immatics Announces Third Quarter 2022 Financial Results and Business Update

November 16, 2022

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

October 9, 2022

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

October 9, 2022

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

September 9, 2022

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

August 22, 2022

Immatics Announces Second Quarter 2022 Financial Results and Business Update

August 8, 2022

Immatics Announces First Quarter 2022 Financial Results and Business Update

June 1, 2022

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

May 17, 2022

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

May 9, 2022

Immatics Announces Full Year 2021 Financial Results and Corporate Update

March 22, 2022

Decks in 2022